NotablePrimary endpoint revisedv5Show 5 more changesShow less
Trial status: Active, Not Recruiting to Completed
Primary and study completion dates changed from estimate of Aug 2010 to Jul 2010
Interventions: valproic acid (Drug) to Placebo (Drug), valproic acid (Drug)
Study arms: 0 to 2
Study title expanded, about 1 word
MinorTrial status: Recruiting to Active, Not Recruitingv4Show 7 more changesShow less
Enrollment target: estimated 36 to confirmed 28
Primary completion date: Aug 2010
Study completion date: Jun 2009 to Aug 2010
Eligibility criteria revised
Secondary endpoint revised
Site details revised at 4 of 4 sites
Study title shortened, about 2 words
Study Status, Conditions, Eligibilityv3
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 4
Start date: Oct 2006 to Nov 2006
v2
Study First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Progressive Supranuclear Palsy (PSP) is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction. Abnormal neuronal and glial tau aggregations affecting the basal ganglia and selective brainstem structures result in dysfunction of the five frontosubcortical circuits and brainstem functions. There is no effective treatment for PSP. One of the key feature in the aggregation of tau is its phosphorylation by kinases such as glycogen synthase kinase 3b (GSK3b). Recent reports have shown that valproic acid was able to inhibit the activity of GSK3b and could exert a neuroprotective effect through this inhibition. The investigators thus decided to conduct this controlled study to assess the putative neuroprotective effects in patients with PSP.